Merck (MRK) Liabilities and Shareholders Equity (2009 - 2026)

Merck (MRK) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $128.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 11.78% year-over-year to $128.7 billion; the TTM figure through Mar 2026 stood at $512.6 billion (up 10.86% YoY), while the FY2025 annual figure was $136.9 billion, up 16.87% from the prior year.
• Liabilities and Shareholders Equity retreated to $128.7 billion in Q1 2026 per MRK's latest filing, from $136.9 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $136.9 billion in Q4 2025 and bottomed at $104.5 billion in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $113.9 billion across 5 years, with a median of $109.2 billion in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 18.09% — and 2023, when it retreated 2.45%.
• Merck's Liabilities and Shareholders Equity stood at $109.2 billion in 2022, then decreased by 2.28% to $106.7 billion in 2023, then advanced by 9.78% to $117.1 billion in 2024, then advanced by 16.87% to $136.9 billion in 2025, then slipped by 5.98% to $128.7 billion in 2026.
• Business Quant data shows MRK's Liabilities and Shareholders Equity at $128.7 billion in Q1 2026, $136.9 billion in Q4 2025, and $129.5 billion in Q3 2025.